The biopharmaceutical firm reports a wider-than-expected per-share loss for the quarter, missing analyst estimates.
Palvella Therapeutics reported a GAAP loss of $1.20 per share, reflecting deeper losses than anticipated by market analysts. The figure underscores ongoing investment in drug development and clinical trials for rare genetic disorders.
Analysts had projected a narrower loss, with consensus estimates closer to $1.00 per share. The company’s prior quarter loss stood at $0.95 per share, indicating an accelerated burn rate as it advances its pipeline.
Shares showed limited movement in after-hours trading, as investors weighed the loss against long-term growth potential in its therapeutic portfolio.